Kerstin Huebner, Katharina Erlenbach-Wuensch, Jan Prochazka, Ilir Sheraj, Chuanpit Hampel, Blanka Mrazkova, Tereza Michalcikova, Jolana Tureckova, Veronika Iatsiuk, Anne Weissmann, Fulvia Ferrazzi, Philipp Kunze, Enise Nalli, Elisabeth Sammer, Annemarie Gehring, Marie M Cheema, Markus Eckstein, Eva-Maria Paap, Agnes Soederberg, Corinna Fischer, Sushmita Paul, Vijayalakshmi Mahadevan, Benardina Ndreshkjana, Melanie A Meier, Susanne Muehlich, Carol I Geppert, Susanne Merkel, Robert Grutzmann, Adriana Roehe, Sreeparna Banerjee, Arndt Hartmann, Radislav Sedlacek, Regine Schneider-Stock
In cancer, the activating transcription factor 2 (ATF2) has pleiotropic functions in cellular responses to growth stimuli, damage, or inflammation. Due to only limited studies, the significance of ATF2 in colorectal cancer (CRC) is not well understood. We report that low ATF2 levels correlated with worse prognosis and tumor aggressiveness in CRC patients. NanoString gene expression and ChIP analysis confirmed trophoblast cell surface antigen 2 (TROP2) as a novel inhibitory ATF2 target gene. This inverse correlation was further observed in primary human tumor tissues...
July 15, 2022: Cellular and Molecular Life Sciences: CMLS